SMFR - SMFR STOCK NEWS

Sema4 (Nasdaq: SMFR) has announced its participation in the 41st Annual J.P. Morgan Healthcare Conference, taking place in San Francisco. The company's President & CEO, Katherine Stueland, will make a presentation on January 12, 2023, at 10:30 a.m. PT. Interested parties can access a live and archived webcast of the event via the Sema4 investor relations website. Sema4 is focused on leveraging AI and machine learning to enhance healthcare by providing data-driven insights through its innovative platform, Centrellis.

Sema4 (Nasdaq: SMFR) announced a study emphasizing the importance of mitochondrial DNA (mtDNA) testing alongside rapid exome sequencing for diagnosing mitochondrial diseases in newborns. Conducted on 966 infants in NICU, the study found that nearly 10% were diagnosed with mitochondrial disorders, with mtDNA testing contributing 1.3% to diagnoses. The findings suggest that earlier detection can lead to improved clinical management, potentially reducing the diagnostic journey for critically ill patients. Sema4 leads in genetic research with a database exceeding 400,000 clinical exomes.

Sema4 Holdings Corp. (Nasdaq: SMFR) announced a strategic pivot towards its pediatric and rare disease business, highlighting strong growth metrics from its diagnostics and data platforms. For Q3 2022, pro forma revenue surged by 21% year-over-year to $83.2 million, with testing volumes increasing 19%. The company aims for annual revenue growth exceeding 20% and adjusted gross margins over 50% by 2025. Key developments include exiting the reproductive health market and substantial partnerships to enhance data capabilities.

Sema4 (Nasdaq: SMFR) will release its third-quarter 2022 financial results on November 14, 2022, before market opening. CEO Katherine Stueland and CFO Kevin Feeley will host a conference call at 8:30 a.m. ET to discuss the results. Sema4 is a health intelligence company utilizing AI and machine learning to enhance healthcare through data insights. Their Centrellis® platform aims to provide comprehensive understandings of health and disease. For more information, visit sema4.com.

Sema4 (Nasdaq: SMFR) supports the National Society of Genetic Counselors' new guidelines recommending exome sequencing as the first-tier test for individuals with unexplained epilepsy. This is a significant step forward, as many cases of unexplained epilepsy have genetic causes that can impact treatment and management. The guidelines aim to reduce the lengthy diagnosis time, which can average over six years and lead to high healthcare costs. Sema4 advocates for utilizing its extensive clinical exome data to enhance diagnostic accuracy and patient care.

Sema4 (Nasdaq: SMFR) announced promising results from the first phase of the SeqFirst study, highlighting the effectiveness of rapid whole genome sequencing (rWGS) in diagnosing critically ill newborns in the NICU. The study found abnormal results in 63% of the infants sequenced, with health management changes in 88% of cases. Notably, 25% of those with abnormal results were not previously suspected of having a genetic syndrome, underscoring the importance of broad testing. These findings will be presented at the upcoming ASHG Annual Meeting.

Sema4 (Nasdaq: SMFR) has released research indicating that exome and genome sequencing yield 30% fewer inconclusive results compared to multi-gene panel tests. This study, presented at the American Society of Human Genetics Annual Meeting, highlights that genomic sequencing achieves a diagnostic yield of 18% versus 10% from panels. Conducted on over 1.5 million tests, the findings suggest significant improvements in diagnosis and health outcomes. The research emphasizes the value of trio-based genomic testing and its benefits for affected families in resolving diagnostic uncertainties.

Sema4 (Nasdaq: SMFR) presented research at the Child Neurology Society Annual Meeting on October 13, 2022, highlighting the benefits of exome analysis for diagnosing Autism Spectrum Disorders (ASD). The study involved nearly 19,000 patients, revealing that 90% had prior negative tests, contributing to diagnostic delays. Exome sequencing showed a diagnostic rate improvement of 7.9-21%, suggesting its use as a first-tier test. Furthermore, the research identified 1,337 emerging genes associated with ASD, supporting earlier and more efficient testing for better health outcomes.

Sema4 (Nasdaq: SMFR) is a partner in the GUARDIAN study, a groundbreaking initiative utilizing whole genome sequencing (WGS) to screen 100,000 newborns for over 250 preventable and treatable conditions. This study aims to drive early diagnosis and treatment while generating evidence for expanding newborn screening protocols. With a team including Sema4|GeneDX, which has conducted about 400,000 clinical exomes, GUARDIAN seeks to evaluate the health impacts of genomic information. The initiative is open to all newborns in the partner health system in New York City.